Allakos

Redwood City, United States

Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.

$150.0M raised

Sep 2022

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Allakos raised?

Allakos has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2022.

Who are Allakos's investors?

Allakos's investors include Samsara BioCapital, Vivo Capital, New Enterprise Associates, Redmile Group, TCG Crossover.

Where is Allakos headquartered?

Allakos is headquartered in Redwood City, United States.

What does Allakos do?

Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.

What stage is Allakos at?

Allakos is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 19, 2022.

MLA

"Allakos — Funding & Investors." VCBacked, September 19, 2022, https://www.vcbacked.co/company/allakos. Accessed July 2, 2026.

APA

VCBacked. (2022). Allakos — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/allakos

Wikipedia (cite web)

{{cite web |title=Allakos — Funding & Investors |url=https://www.vcbacked.co/company/allakos |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 19, 2022.